Loading…
Employees: 1,298
Size Beijing Aerospace Changfeng (600855.SS) is a China Health Care company (Medical Specialties) with a market value of $832M, the 2666th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.11 on 6 Nov 2026.
Performance Over six months the shares fell 35.0%, against -10.9% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 10.2% over the last twelve months (peer median +15.3%); the operating margin is -18.9% (peer median 10.1%).
Valuation It trades at 5.1× enterprise value to sales against a peer median of 2.7× (5th most expensive of 21).
Capital Return on invested capital runs 17.5 points below its cost of capital (9.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.03B | CN¥1.25B | CN¥1.15B | CN¥1.37B | CN¥1.80B |
| Revenue growth | — | +8% | -16% | -24% | — |
| Gross profit | CN¥251M | CN¥201M | CN¥190M | CN¥211M | CN¥435M |
| EBITDA | n/a | -CN¥103M | -CN¥206M | -CN¥181M | CN¥55.8M |
| Net income | -CN¥164M | -CN¥172M | -CN¥246M | -CN¥235M | CN¥5.48M |
| Free cash flow | -CN¥45.9M | -CN¥41.8M | -CN¥80.0M | -CN¥93.2M | -CN¥157M |
| Capital expenditure | CN¥24.7M | CN¥27.2M | CN¥67.8M | CN¥89.7M | CN¥80.6M |
| Total debt | CN¥177M | CN¥239M | CN¥343M | CN¥375M | CN¥387M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600855.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.5% | -5.3% | 9th highest of 21 |
| 6-month return | -35.0% | -10.9% | 3rd lowest of 21 |
| Distance from 52-week high | -59.6% | -30.2% | lowest of 21 |
| Revenue growth (TTM) | -10.2% | +15.3% | lowest of 21 |
| Operating margin | -18.9% | 10.1% | 2nd lowest of 21 |
| EV / Sales | 5.1× | 2.7× | 5th most expensive of 21 |
| ROIC minus cost of capital | -17.5 pp | +1.3 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | 5.1× | n/a | n/a |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | 3.4× | n/a | n/a |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 9.7× | n/a | n/a |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 2.9× | 19.6% | +21.4% |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 2.5× | 9.2% | -10.2% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 4.0× | 5.5% | +105.8% |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | 4.9× | n/a | n/a |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 1.4× | n/a | n/a |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 6.8× | 21.1% | +24.2% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 3.7× | 2.9% | +20.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 1.2× | -7.2% | +11.7% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | 1.6× | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 0.9× | -8.0% | +6.6% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 9.1× | 31.0% | +9.9% |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | 8.9× | n/a | n/a |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 1.7× | -7.0% | +11.3% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 4.1× | -2.1% | +23.5% |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 1.2× | n/a | n/a |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 2.0× | 0.1% | +15.6% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 0.8× | -12.9% | -1.3% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 0.8× | -0.5% | +4.7% |